{
    "nctId": "NCT00316407",
    "briefTitle": "Lapatinib/Carboplatin/Paclitaxel in Previously Treated Ovarian or Breast Cancer Patients",
    "officialTitle": "Phase I/II Lapatinib Plus Carboplatin and Paclitaxel in Stage III or IV Relapsed Ovarian or Stage IV Breast Cancer Patients",
    "overallStatus": "COMPLETED",
    "conditions": "Ovarian Epithelial Cancer Stage III, Stage IV Ovarian Cancer, Stage IV Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1, PHASE2",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 30,
    "primaryOutcomeMeasure": "Toxicity",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Relapsed (Stage III or IV) ovarian, primary peritoneal, fallopian tube carcinoma patients.\n* Stage IV metastatic breast cancer patients who have failed no more than four previous chemotherapies for Stage IV disease.\n* Ability to swallow and retain oral medications.\n* Measurable disease\n\nExclusion Criteria:\n\n* Treatment with previous weekly carboplatin and paclitaxel.\n* No prior treatment with erbB targeting therapies such as erlotinib, gefitinib and cetuximab.\n* No concomitant requirement for medication classification as CYP3A4 inducers or inhibitors.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}